Bioequivalence Assessment of Cannabidiol (CBD) Administrated in Oral Formulations

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The oral bio-availability of cannabidiol (CBD) is low due to poor water solubility and susceptibility to extensive first pass metabolism, resulting in relative bio-availability of 6%.This project is designed to evaluate the plasma concentration vs. time profile of a self emulsifying drug delivery system termed Long Chain Nano Lipospheres (LNL) for enhancing the oral bio-availability of cannabidiol (CBD). The main goal of this study is to evaluate the bio-equivalence of CBD in the LNL product, compared to CBD in a sesame oil vehicle and CBD without any formulation, in powder form. Bio-equivalence is measured by AUC 0-24h, Tmax and Cmax.
Epistemonikos ID: 54c6921bbbcde492f7e9749bd6c910f074d1ea6e
First added on: May 22, 2024